Welcome to the CCO Site

Thank you for your interest in CCO content. As a guest, please complete the following information fields. These data help ensure our continued delivery of impactful education. 

Become a member (or login)? Member benefits include accreditation certificates, downloadable slides, and decision support tools.

Submit

Answering the Questions on Switching ART With Virologic Suppression

Hear from expert faculty as they answer questions and discuss key considerations when determining whether and how to switch antiretroviral therapy in virologically suppressed individuals with HIV.
Tristan J. Barber, MA, MD, FRCP
Darcy Wooten, MD
Released: October 19, 2022

In this episode, Tristan J. Barber, MA, MD, FRCP, and Darcy Wooten, MD, discuss switching ART with virologic suppression, including:

  • Switching with prior or unknown resistance
    • Data on switching to BIC/FTC/TAF with a preexisting M184V/I mutation from a pooled analysis of 6 phase III studies
    • The impact of baseline resistance on outcomes following a switch to BIC/FTC/TAF in Black PWH from the BRAAVE 2020 study
    • A post hoc analysis of the SALSA study of DTG/3TC outcomes at Week 48 by baseline resistance
    • Data from the SOLAR 3D study on switching to DTG/3TC from a 3- or 4-drug ART regimen with a history of M184V
    • A retrospective analysis of switching to DTG/3TC with archived M184V/I from the French Dat’AIDS Cohort
  • Switching to long-acting ART
    • Guidance on candidates for LA CAB + RPV
    • Data on risk factors for virologic failure with LA CAB + RPV
  • Considering an ART switch after weight gain
    • Data on weight gain after ART initiation by ARV class and drug
    • Mean change in weight by sex at Week 96 in the ADVANCE study
    • DHHS guideline recommendations regarding weight gain with ART

Information on this Educational Activity

Faculty

Tristan J. Barber, MA, MD, FRCP

Honorary Associate Professor
Institute for Global Health
University College London
Consultant in HIV Medicine
Ian Charleson Day Centre
Royal Free Hospital
London, United Kingdom

Tristan J. Barber, MA, MD, FRCP: consultant/advisor/speaker: Gilead Sciences, Merck, Roche, Theratechnologies, ViiV Healthcare; researcher: Roche, ViiV Healthcare; unrestricted educational grant holder: Gilead Sciences.
Darcy Wooten, MD

Associate Professor of Medicine
Division of Infectious Diseases and Global Public Health
Department of Medicine
University of California, San Diego
San Diego, California

Darcy Wooten, MD, has no relevant financial relationships to disclose.

Program Medium

This program has been made available online.

Acknowledgements

Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
Gilead Sciences, Inc.
ViiV Healthcare

Related Content

Get expert updates on ART safety and tolerability from fall conferences, from Clinical Care Options (CCO)

Eric K. Farmer, PharmD, BCPS, AAHIVP Darcy Wooten, MD Physicians: maximum of 0.5 AMA PRA Category 1 Credits Registered Nurses: 0.5 Nursing contact hours Pharmacists: 0.5 contact hours (0.05 CEUs) Released: January 24, 2023 Expired: January 23, 2024

European pioneers discuss the latest data and guideline recommendations for implementing LA ART into practice, from Clinical Care Options (CCO)

Celia Jonsson-Oldenbuettel, MD, PhD
Program Director
person default Tom Stephane De Wit, MD, PhD Eric Florence, MD, PhD Mireia SantaCreu Guerrero, MSN person default Laurence Slama, MD, PhD
Physicians: maximum of 1.5 AMA PRA Category 1 Credits Released: January 20, 2023 Expired: January 19, 2024

Dr Eric Florence discusses clinic adaptations to promote successful integration of long-acting injectables for HIV in this commentary from Clinical Care Options (CCO)

Eric Florence, MD, PhD Released: January 17, 2023

Listen to expert faculty discuss strategies to promote ART safety and tolerability in aging patients and populations with cardiometabolic toxicities, from Clinical Care Options (CCO)

Marta Boffito, MD, PhD, FRCP Jens D. Lundgren, MD, DMSc Released: January 17, 2023

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings